Publications by authors named "Huw D Thomas"

Claim this Profile
C
Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.
Hannah L Stewart, Cinzia Bordoni, Claire E Jennings, Islam Al-Khawaldeh, Mathew P Martin, Huw D Thomas

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.
Pasquale A Morese, Nahoum Anthony, Michael Bodnarchuk, Claire Jennings, Mathew P Martin, Huw D Thomas

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance.
Jill E Hunter, Amy E Campbell, Jacqueline A Butterworth, Helene Sellier, Nicola L Hannaway, Huw D Thomas

Biochem J· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.
Islam Al-Khawaldeh, Mohammed J Al Yasiri, Gregory G Aldred, Christine Basmadjian, Cinzia Bordoni, Huw D Thomas

J Med Chem· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway.
Alex Bainbridge, Scott Walker, Joseph Smith, Kathryn Patterson, Aparna Dutt, Huw D Thomas

Nucleic Acids Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
Catherine E Willoughby, Yanyan Jiang, Huw D Thomas, Elaine Willmore, Suzanne Kyle

J Clin Invest· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Stephanie M Myers, Duncan C Miller, Lauren Molyneux, Mercedes Arasta, Ruth H Bawn, Huw D Thomas

Eur J Med Chem· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Lindi Chen, Fabio Pastorino, Philip Berry, Jennifer Bonner, Calum Kirk, Huw D Thomas

Int J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.
Gilberto S Almeida, Carlo M Bawn, Martin Galler, Ian Wilson, Huw D Thomas

NMR Biomed· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterisation of a novel ovarian cancer cell line, NUOC-1.
Aiste McCormick, Eleanor Earp, Katherine Elliot, Gavin Cuthbert, Rachel O'Donnell, Huw D Thomas

Oncotarget· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.
Emma J Haagensen, Huw D Thomas, Wolfgang A Schmalix, Andrew C Payne, Lara Kevorkian

Cancer Chemother Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Gary Beale, Emma J Haagensen, Huw D Thomas, Lan-Zhen Wang, Charlotte H Revill

Br J Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Emma J Haagensen, Huw D Thomas, Clare Mudd, Elpida Tsonou, Ceri M Wiggins

Eur J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hiu-Fung Yuen, Declan O'Rourke, Huw D Thomas

PLoS One· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The conditioned place preference test for assessing welfare consequences and potential refinements in a mouse bladder cancer model.
John V Roughan, Claire A Coulter, Paul A Flecknell, Huw D Thomas, Kenneth J Sufka

PLoS One· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.
Liam Cornell, Joanne M Munck, Clara Alsinet, Augusto Villanueva, Laura Ogle, Huw D Thomas

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Emma J Haagensen, Huw D Thomas, Ian Wilson, Suzannah J Harnor, Sara L Payne

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.
Anastasia C Hepburn, Rajan Veeratterapillay, Stuart C Williamson, Amira El-Sherif, Neha Sahay, Huw D Thomas

PLoS One· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
Christopher R Hill, David Jamieson, Huw D Thomas, Colin D A Brown, Alan V Boddy

Biochem Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
Ian W H Jarvis, Emma L Meczes, Huw D Thomas, Richard J Edmondson, Gareth J Veal

Biochem Pharmacol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Majid Ali, Marzieh Kamjoo, Huw D Thomas, Suzanne Kyle, Ivanda Pavlovska

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.
Huw D Thomas, Lan-Zhen Wang, Celine Roche, Johanne Bentley, Yuzhu Cheng

Eur J Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.
Tomasz Zaremba, Huw D Thomas, Michael Cole, Sally A Coulthard, Elizabeth R Plummer

Biochem J· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Neil Johnson, Yu-Chen Li, Zandra E Walton, Katherine A Cheng, Danan Li, Huw D Thomas

Nat Med· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.
Kappusamy Saravanan, Hannah C Barlow, Marion Barton, A Hilary Calvert, Bernard T Golding, Huw D Thomas

J Med Chem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis